title: EFFECT OF SELENIUM SUPPLEMENTATION ON PROTEOMIC SERUM BIOMARKERS IN ELDERLY MEN.
abstract: OBJECTIVE
  To determine the effect of selenium supplementation on the human proteomic profile.
  
  
  METHODS
  Serum samples were collected in this pilot study from a randomized placebo controlled Phase 2 clinical trial (Watchful Waiting (WW)).
  
  
  METHODS
  Subjects were followed every three months for up to five years at the University of Arizona Prostate Cancer Prevention Program.
  
  
  METHODS
  One hundred and forty men (age < 85 years) had biopsy-proven prostate cancer, a Gleason sum score less than eight, no metastatic cancer, and no prior treatment for prostate cancer.
  
  
  METHODS
  As part of the WW trial, men were randomized to placebo, selenium 200 μg/day or selenium 800 μg/day. For the purpose of the current study, 40 subjects enrolled in the WW study (20 from the placebo group and 20 from Se 800 μg/day group) were selected.
  
  
  METHODS
  Baseline serum samples were collected at each follow-up visit and stored at -80 degrees Celsius. A multiplexed proteomic panel investigated changes in 120 proteins markers simultaneously.
  
  
  RESULTS
  Thirteen proteins (Apolipoprotein J, IL-10, IL-1 alpha, MMP-3, IL-12p70, IL-2 receptor alpha, cathepsin B, eotaxin, EGFR, FGF-basic, myeloperoxidase, RANTES, TGF-beta) were determined to be either statistically (p-value < 0.05) or marginally significantly (0.05 < p-value <0.1) changed in the selenium supplemented group as compared to placebo.
  
  
  CONCLUSIONS
  Although independent validation of these results is needed, this study is the first of its kind to utilize high throughput fluorescence based protein multiplex panel in analyzing changes in the proteomic profile due to selenium supplementation. Results from this study provide insight into the ability of selenium to modulate numerous protein markers and thus impact various biological processes in humans.
authors.affiliation: Department of Preventive Medicine, Loma Linda University Medical Center, Loma Linda, CA ; University of Arizona Cancer Center, Tucson, AZ.
authors.forename: A M
authors.initials: AM
authors.lastname: Algotar
authors.affiliation: University of Arizona Cancer Center, Tucson, AZ.
authors.forename: R
authors.initials: R
authors.lastname: Behnejad
authors.affiliation: Department of Hematology-Oncology, University of Arizona, Tucson, AZ.
authors.forename: P
authors.initials: P
authors.lastname: Singh
authors.affiliation: Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ.
authors.forename: P A
authors.initials: PA
authors.lastname: Thompson
authors.affiliation: Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ.
authors.forename: C H
authors.initials: CH
authors.lastname: Hsu
authors.affiliation: University of Arizona Cancer Center, Tucson, AZ.
authors.forename: S P
authors.initials: SP
authors.lastname: Stratton
keywords: Selenium supplementation; elderly men; proteomic biomarkers